Catalog No. : CBB-F011001-C-L

ClearCell® FX1 Unit CE-IVD Lease

ClearCell® FX1 Unit CE-IVD Lease


Driven by CTChip® FR

The ClearCell® FX1 System, driven by the CTChip® FR, is one of the world’s first automated cell retrieval systems that can enrich wholly intact and viable Circulating Tumour Cells (CTCs) from small amounts of blood in a relatively short time.

Combined with the high levels of purity, the CTCs are enriched in suspension, which allows for easy integration with downstream molecular analyses and diagnostic assays. This means that researchers and clinicians can use these insights to provide timely, tailored treatment options.



  • Label-Free Liquid Biopsy System
  • Label-free CTC enrichment fo heterogeneous populations of cancer cells
  • Up to 10,000x enrichment of CTCs that are wholly intact and viable
  • Large blood volume enrichment from 7.5ml of patients' blood
  • Automated workflow and fast processing time of < 1h
  • Sensitive, with a high dynamic range
  • Easy and ready integration with a wide variety of downstream molecular and pathology applications
  • CE-IVD and ISO 13485 certified

Cancer Facts

More than 80% of all cancer patients die from metastasis, not the actual primary tumour. Cancer is complex, heterogeneous and dynamic. For the patient, a cancer treatment journey drains physically, emotionally, mentally and financially. For the oncologist, it may mean questions of possible overtreatment and having to subject patients to frequent, painful biopsies. Over the course of treatment, the cancer can evolve and become resistant, making treatment decisions challenging and potentially sub-optimal.

Therefore the ability to precisely detect these changes facilitates timely diagnosis and staging of the disease; this ability is critical for precise, tailored treatment and proactive monitoring. This is where Circulating Tumour Cells (CTCs) become critically relevant.

Significance of CTCs

Circulating Tumour Cells (CTCs) are extremely rare cells that have detached from solid tumours, travel in the bloodstream and can cause the cancer to spread. They are considered the seeds of metastasis and could be a clear indication of disease progression.

A blood test, or liquid biopsy that can detect and profile these CTCs presents a quick, non-invasive way to obtain real-time information about the cancer disease status. In combination with other diagnostic methods, doctors may be able to design specific responses to fight the diagnosed cancer.

Combining this insight with the ability to match drugs according to disease mutation and resistance, isolating wholly intact CTCs could be the potential gold standard for the detection of cancer metastasis.

All from a simple blood draw.

Our Technology to help

Fully automated and entirely label-free, Clearbridge BioMedics’ ClearCell® FX1 System, with the patented microfluidic biochip, CTChip® FR1, the ClearCell® FX1 System achieves label-free CTC enrichment that better addresses the dynamic and complex nature of cancer. It even provides the potential for serial real-time treatment monitoring.

Price per month. Excludes servicing and warranty.
ItemSize Application Price
ClearCell® FX1 Unit CE-IVD Lease

1 Package

Automation Cell Culture Please Inquire


ClearCell® FX1 Unit CE-IVD x 1

ClearCell® FX1 Installation Run Kit CE-IVD x 1


Fluorescence In Situ Hybridisation (FISH)

Fluorescence in situ hybridisation (FISH) is an established cytogenetic technique used in pathology laboratories for tumour profiling and screening of genetic aberrations, such as gene translocation, amplification and deletions. It is also the current gold standard for selection of cancer patient eligible for HER2 and ALK targeted drug therapy. …

Read More

Cell Culture

The emergence of novel technologies offers a new avenue to obtain circulating tumour cells (CTCs) for understanding metastasis. CTCs are extremely rare in circulation and the isolation of intact and viable cells is non-trivial. Use of affinity based methods and magnetic beads based methods could potentially impact cellular phenotypes and viability …

Read More

Molecular Analysis

KRAS is an oncogene with extremely high incidence of mutations. KRAS mutations have been seen in approximately 25% of all cancer types and 30-40% of colorectal cancer (Arrington et al. 2012). It is also associated with poorer prognosis and treatment response in colorectal and lung cancer. As such, there is significant interest in molecular testing of KRAS mutation. …

Read More

Immunofluorescence (IF) / Immunocytochemistry (ICC)

This application note describes the label-free enrichment of CTCs or microemboli from blood sample using the ClearCell® FX platform followed by immunofluorescence assay

Read More

Video Guide

Contact Us at for more information.

Scientific Resources:


  • Arutha Kulasinghe, Chris Perry, Liz Kenny, Tony Blick, Majid Warkiani, Ian Vela, Ken O'Byrne, Jean-Paul Thiery, Erik Thompson, Colleen Nelson, Chamindie Punyadeera. Circulating tumor cells: The tumor trail left in the blood [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5572.
  • Chen et al., 2018, “Impeding Circulating Tumor Cell Reseeding Decelerates Metastatic Progression and Potentiates Chemotherapy” Molecular Cancer Research, December 2018 Volume 16, Issue 12.
  • Garcia et al., 2018, “Comparison of OncoBEAM and NGS methods to do plasma EGFR p.T790M mutation during progression in non small cell Lung cancer”, ESMO 2018.
  • Lee et al. 2018, “ClearCell® FX, a label‐free microfluidics technology for enrichment of viable circulating tumor
  • Ramalingam et al., 2018, “Marker-Free microfluidic enrichment enables full-length mRNA transcriptome analysis of single live circulating tumors cells from six Breast cancer subjects, Single Cell Genomics 2018.
  • Schneegans et al., 2018, “Impact of Blood Collection Tubes on CTC-, ctDNA- and miRNA recoveries in malignant melanoma patients” AACR Annual Meeting 2018
  • Xu et al., 2018, “Xenograft tumors derived from malignant pleural efusion of the patients with non- small-cell lung cancer as models to explore drug resistance”, Cancer Communications2018: 38:19
  • Yin et al. 2018, “Characterization of circulating tumor cells in breast cancer patients by spiral microfluidics”
Please Inquire

Related Products

ItemSizeMakeCatalog No.ApplicationPriceQty
CTChip® FR1S CE-IVD Biolidics CBB-FR001002-C

Related Products